A Swiss recreational cannabis pilot has been linked to reductions in depression and anxiety symptoms and less problematic use, despite participants consuming cannabis on slightly more days per month.
The study, published in Drug and Alcohol Dependence, analysed 374 regular cannabis users during the first year of Basel’s Weed Care project, which began in January 2023.
Average depression and anxiety scores fell slightly over the year. The clearest improvement in problematic use was among participants whose cannabis use was most concerning at the outset.
Participants used cannabis on an average of 20.1 days a month after a year, up from 18.7. The amount consumed on each day of use did not change significantly.
In the higher-risk group, average scores on a questionnaire assessing problematic cannabis use fell from 16.1 to 13.9, remaining slightly above the threshold of 13 for possible cannabis use disorder.
The researchers concluded that “these findings suggest that regulated access was not associated with deterioration in mental health or cannabis use”.
The pilot is one of many running across different regions in Switzerland. Under the scheme’s original plans, existing adult cannabis users could register to purchase cannabis from nine pharmacies. Products were quality-controlled and labelled with tetrahydrocannabinol (THC) and cannabidiol (CBD) content, with THC levels capped at 20%.
Monthly purchases were limited to the equivalent of ten grams of THC, with the amount of cannabis available depending on potency. Pharmacists were trained to explain lower-risk consumption and recognise signs that someone needs further help, including referral to a study doctor or treatment service.
A separate Swiss government-commissioned evaluation of seven pilot schemes also reported early improvements in anxiety and depression, suggesting that removing the stress of illegal purchases could help explain those changes. Participants also described benefits from buying cannabis without the stigma associated with the illegal market.
In a three-year update published in March 2026, the University of Basel reported continued reductions in problematic use and improvements in mental health among Weed Care participants. The project has been extended until January 2027, with a final report expected in 2027.

















